2023 Boca Raton Regional Hospital Internal Medicine Symposium Evaluation - Day 1

Please score your agreement with or assessment of the following questions and statements by rating on a scale of 1 to 5, with 5 representing the highest level of satisfaction or agreement. *

Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree

	5	4	3	2	1
The information and/or skills learned will enhance my professional competence or ability.	The information and/or skills learned will enhance my professional competence or ability. - 5	The information and/or skills learned will enhance my professional competence or ability. - 4	The information and/or skills learned will enhance my professional competence or ability. - 3	The information and/or skills learned will enhance my professional competence or ability. - 2	The information and/or skills learned will enhance my professional competence or ability. - 1
This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients.	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 5	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 4	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 3	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 2	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 1

How confident are you in your ability to: *

5 = High level of confidence 4 = Moderately high level of confidence 3 = Average level of confidence 2 = Low level of confidence 1 = No level of confidence Not applicable|Not applicable

	5	4	3	2	1	Not applicable
Identify novel approaches for treating underling metabolic risk as the pre-eminent driver of "residual risk".	Identify novel approaches for treating underling metabolic risk as the pre-eminent driver of "residual risk". - 5	Identify novel approaches for treating underling metabolic risk as the pre-eminent driver of "residual risk". - 4	Identify novel approaches for treating underling metabolic risk as the pre-eminent driver of "residual risk". - 3	Identify novel approaches for treating underling metabolic risk as the pre-eminent driver of "residual risk". - 2	Identify novel approaches for treating underling metabolic risk as the pre-eminent driver of "residual risk". - 1	Identify novel approaches for treating underling metabolic risk as the pre-eminent driver of "residual risk". - Not applicable
Introduce and discuss newest preventives, and when they would be used	Introduce and discuss newest preventives, and when they would be used - 5	Introduce and discuss newest preventives, and when they would be used - 4	Introduce and discuss newest preventives, and when they would be used - 3	Introduce and discuss newest preventives, and when they would be used - 2	Introduce and discuss newest preventives, and when they would be used - 1	Introduce and discuss newest preventives, and when they would be used - Not applicable
Identify the advantages and disadvantages of the use of GLP-1 receptor agonists.	Identify the advantages and disadvantages of the use of GLP-1 receptor agonists. - 5	Identify the advantages and disadvantages of the use of GLP-1 receptor agonists. - 4	Identify the advantages and disadvantages of the use of GLP-1 receptor agonists. - 3	Identify the advantages and disadvantages of the use of GLP-1 receptor agonists. - 2	Identify the advantages and disadvantages of the use of GLP-1 receptor agonists. - 1	Identify the advantages and disadvantages of the use of GLP-1 receptor agonists. - Not applicable

How satisfied or dissatisfied were you with the Speaker's effectiveness in addressing the learning objectives? *

Scoring Key: 5=Strongly satisfied 4= Somewhat satisfied 3=Neither satisfied nor dissatisfied 2= Somewhat dissatisfied 1=Strongly dissatisfied NA= Not Applicable

	5	4	3	2	1	NA
Keynote Presentation - Reflections on the COVID-19 Pandemic: Vaccines, Human Behavior, and the Circle of Least Confusion - Gregory Poland, M.D.	Keynote Presentation - Reflections on the COVID-19 Pandemic: Vaccines, Human Behavior, and the Circle of Least Confusion - Gregory Poland, M.D. - 5	Keynote Presentation - Reflections on the COVID-19 Pandemic: Vaccines, Human Behavior, and the Circle of Least Confusion - Gregory Poland, M.D. - 4	Keynote Presentation - Reflections on the COVID-19 Pandemic: Vaccines, Human Behavior, and the Circle of Least Confusion - Gregory Poland, M.D. - 3	Keynote Presentation - Reflections on the COVID-19 Pandemic: Vaccines, Human Behavior, and the Circle of Least Confusion - Gregory Poland, M.D. - 2	Keynote Presentation - Reflections on the COVID-19 Pandemic: Vaccines, Human Behavior, and the Circle of Least Confusion - Gregory Poland, M.D. - 1	Keynote Presentation - Reflections on the COVID-19 Pandemic: Vaccines, Human Behavior, and the Circle of Least Confusion - Gregory Poland, M.D. - NA
Pulmonary Year in Review - Margaret Johnson, M.D.	Pulmonary Year in Review - Margaret Johnson, M.D. - 5	Pulmonary Year in Review - Margaret Johnson, M.D. - 4	Pulmonary Year in Review - Margaret Johnson, M.D. - 3	Pulmonary Year in Review - Margaret Johnson, M.D. - 2	Pulmonary Year in Review - Margaret Johnson, M.D. - 1	Pulmonary Year in Review - Margaret Johnson, M.D. - NA
Update in Cystic Fibrosis for Generalist: Why Does it Matter? - Margaret Johnson, M.D.	Update in Cystic Fibrosis for Generalist: Why Does it Matter? - Margaret Johnson, M.D. - 5	Update in Cystic Fibrosis for Generalist: Why Does it Matter? - Margaret Johnson, M.D. - 4	Update in Cystic Fibrosis for Generalist: Why Does it Matter? - Margaret Johnson, M.D. - 3	Update in Cystic Fibrosis for Generalist: Why Does it Matter? - Margaret Johnson, M.D. - 2	Update in Cystic Fibrosis for Generalist: Why Does it Matter? - Margaret Johnson, M.D. - 1	Update in Cystic Fibrosis for Generalist: Why Does it Matter? - Margaret Johnson, M.D. - NA
Residual Risk Assessment and Cardiometabolic Syndrome - Michael J. Blaha, M.D., MPH	Residual Risk Assessment and Cardiometabolic Syndrome - Michael J. Blaha, M.D., MPH - 5	Residual Risk Assessment and Cardiometabolic Syndrome - Michael J. Blaha, M.D., MPH - 4	Residual Risk Assessment and Cardiometabolic Syndrome - Michael J. Blaha, M.D., MPH - 3	Residual Risk Assessment and Cardiometabolic Syndrome - Michael J. Blaha, M.D., MPH - 2	Residual Risk Assessment and Cardiometabolic Syndrome - Michael J. Blaha, M.D., MPH - 1	Residual Risk Assessment and Cardiometabolic Syndrome - Michael J. Blaha, M.D., MPH - NA
What's New in the 2022 Heart Failure Guidelines? - Richa Gupta, M.D., MPH	What's New in the 2022 Heart Failure Guidelines? - Richa Gupta, M.D., MPH - 5	What's New in the 2022 Heart Failure Guidelines? - Richa Gupta, M.D., MPH - 4	What's New in the 2022 Heart Failure Guidelines? - Richa Gupta, M.D., MPH - 3	What's New in the 2022 Heart Failure Guidelines? - Richa Gupta, M.D., MPH - 2	What's New in the 2022 Heart Failure Guidelines? - Richa Gupta, M.D., MPH - 1	What's New in the 2022 Heart Failure Guidelines? - Richa Gupta, M.D., MPH - NA
Regenerative Medicine in Cardiovascular Disease - Emerson Carvalho Perin, M.D., Ph.D.	Regenerative Medicine in Cardiovascular Disease - Emerson Carvalho Perin, M.D., Ph.D. - 5	Regenerative Medicine in Cardiovascular Disease - Emerson Carvalho Perin, M.D., Ph.D. - 4	Regenerative Medicine in Cardiovascular Disease - Emerson Carvalho Perin, M.D., Ph.D. - 3	Regenerative Medicine in Cardiovascular Disease - Emerson Carvalho Perin, M.D., Ph.D. - 2	Regenerative Medicine in Cardiovascular Disease - Emerson Carvalho Perin, M.D., Ph.D. - 1	Regenerative Medicine in Cardiovascular Disease - Emerson Carvalho Perin, M.D., Ph.D. - NA
The ABC’s of GLP-1 Agonists for Obesity Management - Daniela Hurtado, M.D., Ph.D.	The ABC’s of GLP-1 Agonists for Obesity Management - Daniela Hurtado, M.D., Ph.D. - 5	The ABC’s of GLP-1 Agonists for Obesity Management - Daniela Hurtado, M.D., Ph.D. - 4	The ABC’s of GLP-1 Agonists for Obesity Management - Daniela Hurtado, M.D., Ph.D. - 3	The ABC’s of GLP-1 Agonists for Obesity Management - Daniela Hurtado, M.D., Ph.D. - 2	The ABC’s of GLP-1 Agonists for Obesity Management - Daniela Hurtado, M.D., Ph.D. - 1	The ABC’s of GLP-1 Agonists for Obesity Management - Daniela Hurtado, M.D., Ph.D. - NA

Was this course fair, balanced and without commercial bias? *

Yes

If you checked "No,” please explain why: *

As a result of my participation in this Symposium, I commit to make the following changes to my clinical practice: *

I will summarize novel approaches for treating underling metabolic risk as the pre-eminent driver of "residual risk".

I will identify the advantages and disadvantages of the use of GLP-1 receptor agonists.

I will implement practices associated with improved clinical outcomes in heart failure.

Not applicable to my practice.

I do not agree with the recommendations presented.

I am retired.

What, if any, new skills/strategies will you apply in your clinical practice? *

What are the potential barriers or obstacles that might prevent you from implementing new strategies you learned at this activity? *

Comments

Name

Attestation *

Choose 1 option

I attest that I have participated in this live virtual symposium in its entirety.

I attest that I have participated in _____ hours of instruction during this live webinar.

hours attestation *

Hours attended

Leave this field blank

You are here

2023 Boca Raton Regional Hospital Internal Medicine Symposium Evaluation - Day 1